A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection.
Latest Information Update: 16 Jan 2017
At a glance
- Drugs XTL 6865 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors XTL Biopharmaceuticals
- 29 Mar 2007 Status changed from recruiting to completed.
- 21 Oct 2005 New trial record.